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ABSTRACT
The potential regenerative role of different orthobiologics is becoming more recognized for the treatment of
chronic and degenerative musculoskeletal conditions. Over the last few years there has been an increasing number
of publications on cell therapy and other orthobiologics for the treatment of avascular necrosis of the femoral head
and other hip conditions with promising short–term clinical results. In this article, we have used a systematic search
of the literature to identify potentially relevant topics on orthobiologics and then selected those most applicable to
hip preservation surgery. We identified several innovative strategies and present a summary of the currently available
evidence on their potential role in hip preservation surgery. For many of these treatment strategies there was a lack
of clinical evidence and therefore we suggest that there is a need for comparative studies in this field.
INTRODUCTION
Orthobiologics have been defined for a non-specialist audi-
ence as ‘substances that orthopaedic surgeons use to help
injuries heal more quickly’ that are ‘made from substances
naturally found in the body’ which can be used in problems
such as ‘the healing of fractured bones, injured muscles, ten-
dons and ligaments’ [1]. The term ‘Orthobiologic’ can
therefore be considered to refer to a biologically derived ma-
terial used in the regeneration and repair of musculoskeletal
tissues. This would also encompass osteoconductive sub-
stances that provide the conductive medium to facilitate the
in-growth and expansion of the normal tissue [2, 3].
A number of studies reporting on the clinical outcomes
of incorporating these substances in different therapies
identified a spectrum of potential clinical applications [4].
Initially this was in the field of trauma and reconstructive
surgery [2] but there is now a growing recognition for a po-
tential role in chronic and degenerative musculoskeletal
conditions [3–5]. Their utilization in isolation or in
conjunction with traditional surgical procedures in the pre-
vention or the treatment of early degenerative conditions
has thus far yielded promising short-term clinical results
[6–8].
Regenerative medicine is an expanding clinical area
which encompasses both cell and cell-free approaches to
treatment, and can make use of orthobiologics. It is there-
fore no surprise that regenerative and orthobiologic treat-
ments might be considered in hip preservation.
Furthermore, minimally invasive hip surgery in general and
hip arthroscopy specifically have facilitated early interven-
tions and treatment for multiple hip conditions including
early stages of osteoarthritis in young patients [9, 10]. This
has also brought different types of ‘orthobiologics’ into the
spot light of hip preservation surgery.
Therefore our aim was to conduct a systematic litera-
ture search looking for articles reporting the use and out-
come of orthobiologic approaches in hip preservation
surgery.
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LITERATURE SEARCH METHOD
A systematic literature search was conducted using the
EMBASE (between 1974 and November 2014) and
PubMed data bases for entries on orthobiologics and hip
preservation surgery. Initially we searched for any entries
containing the key ward ‘orthobiologics’. There were only
41, and none related to ‘hip preservation surgery’.
However, these were reviewed and used to identify the
common ‘orthobiologic’ substances used in surgery. The
resulting terms were then used for the main literature
search. The first search (search 1) was conducted for re-
cords containing any of the terms relating to ‘orthobio-
logics’ (Table I). The ‘explode’ function on EMBASE
search engine was also used to include any articles contain-
ing any other terms relating to the key words used in the
search. The ‘OR’ function (in PubMed and EMBASE data-
bases search engines) was used to compose a list of all the
hits containing at least one of the search key wards used in
search one. A second search was carried out with the key
words ‘hip’ OR ‘Femoral head’ (search 2). The Explode
function was also used for this search in the EMBASE data
base.
The results of Search 1 and Search 2 were combined
with the function ‘AND’ in both data bases. This yielded a
list of hits (in each data base) containing at least one of the
keywords used in search 1 ‘AND’ at least one of the key-
words used search 2. Only entries in the English language
and in human subjects were selected, yielding a total of
2681 hits in EMBASE and 1473 hits in PubMed. The titles
of these entries were screened in order to identify relevant
articles. For further inclusion, our criteria required titles to
relate broadly to the use of orthobiologics and any form of
hip surgery. If the title was ambiguous then the abstract
was also read to decide on the relevance of the article.
Subsequently, the abstracts of all the identified selected
titles were read to exclude any articles that did not satisfy
our selection criteria. If the abstract was not clear, the full
text was retrieved. This was followed by retrieving the full
text of all the identified relevant articles for review. Animal
or in vitro studies were excluded. Articles on the use of
human bone graft in isolation were excluded unless
synthetic bone graft substitutes were used. We only
included comparative control studies such as case control,
cohort or randomized control studies. Case series and case
reports were only included if no (or small number of)
comparative studies were found. We also cross referenced
all identified articles and systemic reviews to make sure no
relevant articles were missed by the data base searches,
Fig. 1. If more than one article was found on the same
study, then only the latest article with the longest follow-
up was included.
RESULTS
A large number of articles on cell therapy treatment for
Avascular Necrosis of the Femoral Head (AVNFH) were
found. Therefore only clinical comparative control studies,
including five randomized control trials (RCTs), were
included in the review [11–18] (Table II). Case series re-
ports on cell therapy were only referred to in the text if
they had addressed a significant development in cell ther-
apy not covered by the control studies. With regards to the
rest of orthobiologics, there were a very small number of
control studies [19–22] (Table III) and therefore we
included all case series and case reports found during the
literature search [23–56]. Although we have referred to all
these publications, only the main articles are summarized
in this review.
Bone morphogenetic proteins
Bone morphogenetic proteins (BMPs) are members of the
TGF-b superfamily that are implicated in complex signal-
ling pathways in osteoblastic differentiation and osteogen-
esis [2]. Hence they have been shown to possess
oesteogenic activities and promote cartilage formation [2].
The efficacy of BMP-7 in the setting of bone non-union
has been shown to be as effective as autologous bone graft
[57]. Most of the studies we found were of case series
describing the use of BMPs in the treatment of AVNFH.
Table I. The terminologies used for database searches
Search category Keywords
Search1 ‘stem cell’ OR ‘BMP’ OR ‘PRP’ OR ‘thrombocyte rich plasma’ OR ‘HA’ OR ‘bone marrow stem cell’ OR
‘hematopoietic stem cell’ OR ‘peripheral blood stem cell’ OR ‘mesenchymal’ OR ‘mesenchymal stroma
cell’ OR ‘mesenchymal stem cell’ OR ‘cartilage transplantation’ OR ‘cartilage cell’ or ‘cell transplant-
ation’ OR ‘bone graft’ OR ‘bone substitute’ OR ‘autologous chondrocyte implantation’ OR ‘ACI’ or
‘matrix-induced chondrocyte implantation’ OR ‘MACI’ OR ‘chondrocyte implant’.
Search 2 ‘hip’ OR ‘femoral head’
340  Z. Alshameeri and A. McCaskie
Fig. 1. The inclusion and reviewing process of the articles. Some of the final included articles incorporate more than one orthobiolog-
ical substance.
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Lieberman et al. [35] was the first to report on the use
of BMP-7 in a case series of 17 hips (15 patients) with
AVNFH (15 hips ficat stages IIA, one hip stage IIB and
one stage III). Following core decompression and debride-
ment of the necrotic lesion, autologous bone graft from
the greater trochanter was impacted into the necrotic cav-
ity with a gelatine capsule containing 50mg of partially
purified human BMP and non-collagenous protein. The
decompression tract was filled with autolyzed cortical fib-
ula bone graft. At the end of follow-up (mean duration of
53 months) there was no progression in 14 hips (86%), all
from stage IIA. The other 3 hips had radiographic progres-
sion and all converted to total hip arthroplasty (THA).
There was no comparative group and therefore the exact
therapeutic impact of BMP on the overall outcome cannot
be verified. The largest case series on the use of BMPs in
AVNFH was published by Seyler et al. [36]. Their series
included 39 hips, Ficat and Arlet Stage II or III. They used
the trap door technique to make a window at the head–
neck junction to remove the necrotic bone and to pack the
excavated area with autologous cancellous bone graft, mar-
row and OP-1(BMP 7). The overall early clinical success
(no THA) rate was 67% after a mean follow-up period of
36 month. The size of the lesion and the staging of
AVNFH had a significant influence on the survival of the
hips in their series.
The only comparative study found was a cohort
study involving 72 hips and comparing the outcome
of using artificial bone (Novobone) with or without
rhBMP-2 for the treatment of AVNFH [19]. After a mean
follow-up of 6 years, there was no statistically significant
difference between the 2 groups in hip function score or
radiological appearance of the femoral head (Table III).
One of the main complications associated with the use
of BM-7 was highlighted by Papanagiotou et al. [37].
Heterotopic ossification developed in four of their seven
patients but according to the authors this did not affect the
post-operative rehabilitation or compromized the final re-
sults. The disease progressed in three of the seven patients
following the treatment, two required THA (6 months
after treatment).
Platelet rich plasma and hyaluronic acid
A small number of studies have been published on the use
of platelet rich plasma (PRP) in hip conservation surgery
[20, 38–40, 45]. Only one comparative study was found as-
sessing the effect of injecting PRP into the hip joint follow-
ing arthroscopic surgery for labral tears [20]. After a
follow-up period of 2 years the pain level in the PRP-
treated patients was higher than the control group;
however, there were no differences in hip function scores
or rate of revision surgery (Table III).
A study concerning arthroscopic installation of PRP and
bone grafting for the treatment AVNFH has been pub-
lished recently [40]. Core decompression for grade I or
IIA hips was achieved by drilling through the base of the
head and then 10ml of ‘liquid PRP’ was delivered into the
necrotic area. In cases with advanced stage AVNFH (stage
IIB and IIC), full debridement of the necrotic lesion was
carried out by an arthroscopically created window in the
head and neck junction. Autologous bone graft mixed with
PRP was installed into the necrotic area. The authors
described using this technique in three patients with a
mean follow-up of 14 months. All three patients reported a
significant reduction in pain intensity by >60% on a VAS
scale and a return to activities of daily living by 5 months
[40]. The use of PRP in combination with Adipose-tissue-
derived stem cells (obtained from lipo-suction) and hyalur-
onic acid (HA) has also been described in three cases with
early stages of AVNFH [38, 39]. This was injected into the
femoral head under ultrasound guidance. The first two pa-
tients reported a reduction in pain by 70% and 30%, re-
spectively, and filling of the bone defect 12 weeks
following the procedure on MRI [39]. The third case [38]
had further repeated injections of additional PRP into the
osteonecrotic area on weekly bases for 4 weeks. Authors
reported a complete resolution of the necrosis (clinically
and radiologically) 21 months after the procedure but they
had no biopsy to confirm.
Synthetic bone substitutes
The majority of articles relating to bone substitutes re-
ported their use as a mechanical support for the sub-chon-
dral bone in AVNFH, building upon the use of autogenic
and allogeneic bone graft. More recently, other support de-
vices in the form of tantalum rods [15, 53], Nano-hydroxy-
apatite/polyamide 66 rod (n-HA/PA66) [18], porous
calcium hydroxyapatite (IP-CHA) [11], injectable calcium
sulphate (CaSO4)/calcium phosphate (CaPO4) composite
graft [46] and calcium phosphate cement [47] have been
used. Furthermore, the use of cell therapy in combination
with the aforementioned materials has also been described
in [11, 18].
Yang et al. [21] compared the outcome of using nano-
hydroxyapatite/polyamide 66 rod (n-HA/PA66) and
resorbable bioglass bone (NovaBone) graft versus autolo-
gous cancellous bone graft in patients with AVNFH. The
group reported an improved outcome with regards to hip
function score, pain and disease progression with the rod
treatment after 2 years of follow-up (Table III). It should
be noted that the paper was retrospective and that the
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techniques used for the debridement and graft impaction
were different in the two groups.
In a case series, Civinini et al. [46] used an injectable
calcium sulphate (CaSO4)/calcium phosphate (CaPO4)
composite graft injected into the debrided necrotic cavity.
This was augmented with autologous bone marrow con-
centrate to supplement the core decompression in the
treatment of stages 1c–3a AVNFH in 37 hips. With a
mean follow-up of 20 months (range 10–36 months),
there was a significant increase in the Hip Harris Score
(HHS) from a mean of 68–86 points (P< 0.05). Based on
the HHS, 86.5% of patients had excellent or good out-
come. There was radiological progression of the disease in
8 (21.6%) and clinical failure in 5(13.5%) patients
(advanced stages), 3(8.1%) of whom needed THA.
Recently, a dynamic umbrella-shaped titanium alloy
scaffold has been proposed for AVNFH [52]. This device
is inserted via the decompression tunnel and implanted
into the collapsed head. The umbrella is then expanded in
the femoral head and the cavity is backed with autologous
bone graft and artificial bone. Yu et al. [52] reported on
the outcome of using these umbrella devices in 18 patients.
After a mean follow-up time of 19 months, only 2 hips had
a fair and one hip had a poor outcome. The rest had either
good (9 hip) or excellent (5 hips) outcome. One patient
had a major complication when the umbrella was mis-
placed and expanded outside the femoral head resulting in
conversion to THA 10 days following the procedure.
Mini invasive arthroscopic grafting of bone cysts using
cancellous bone and demineralized bone matrix has been
described in two cases by Jamali et al. [48]. One patient had
a cyst in the femoral neck and the other had a similar cyst in
the acetabular rim. There was good filling of the defects and
‘excellent’ clinical outcome 20 and 6 months, respectively fol-
lowing the procedure. The authors recommended the graft
material for this application to be osteoconductive, osteoin-
ductive, malleable and is self-adherent to prevent fragment
release into the joint risking third-body damage [48].
Cell therapy
The use of cell therapy in the hip joint has only recently
been explored and is still largely confined to the treatment
of AVNFH, Table II. The push towards using cell therapy
in the treatment of AVNFH came from the recognition
that the replication capacity of osteoblastic cells and mes-
enchymal stem cells pool are significantly reduced in the
proximal femur of patients with AVNFH [58, 59]. Hence
supplementing the femoral head with viable multipotent
cells could be considered as an appropriate pathophysio-
logical approach for the treatment of this condition [60].
Pre-clinical studies have demonstrated survival of
implanted cells in the necrotic region of the femur result-
ing in new bone formation and neovascularization [61].
The clinical use of Bone Marrow Mononuclear cells
(BMMCs) in the treatment of AVNFH was initiated by
Hernigou et al. in 2002 [62]. A recently published long-
term outcome (follow-up ranging between 8 and 18 years)
reported 17.6% conversion to THA. The rest (82.4%) had
significant improvement in the HHS at the end of the fol-
low-up [60]. They also reported a complete resolution of
the disease in 12.9% of patients (all were ARCO stage 1)
and a reduction in the necrotic lesion size in the rest of the
hips (69.5%) [60]. The lack of a comparative (control)
group in this large case series made it difficult to determine
the exact effectiveness of cell therapy in AVNFH. However
it demonstrated the feasibility of using cell therapy in the
treatment of AVNFH, and the potential of achieving a bet-
ter outcome relative to the traditional surgical treatments.
Over the last 12 years, several clinical control studies
including five RCTs have been published reporting on the
short-term outcome of incorporating multipotent cells
with surgical treatment of early stages of AVNFH [11–18]
(Table II). The mean duration of follow-up ranged from
24 months to 60 months and four of the five studies re-
ported a better outcome in disease progression and clinical
symptoms when cells were incorporated in the surgical
treatment of AVNFH. These found that the time to pro-
gression and conversion to THA was also lower in patients
treated with Cells [11–13, 15, 16, 18]. However based on
the small number of studies, it is not clear whether this had
an impact on the time delay to THA in failed cases [12,
61]. The largest therapeutic difference was observed in the
earlier stages of AVNFH. The therapeutic difference
decreased as the stages of the disease advanced (ARCO
sage I to III); however, the overall effect of combining cell
therapy in treating ARCO stage II and III appeared to be
superior to the standard surgical treatment in the control
groups [11–18].
Attempt to systemically summarize the results of all the
published RCTs (or other control trials) to determine the
overall combined effect of cell therapy has been challeng-
ing [61, 63]. This is because the studies have included co-
hort of patients with different aetiologies for the disease,
used different classification systems for AVNFH and had
different outcome measure scales and different endpoints
(see Table II). A recent meta-analysis has attempted to
analyse the results of four RCTs but could not combine all
the studies into one analysis thus diluting the strength of
the results [63].
Treatment of advanced stages of AVNFH with cells has
been described by one case series. Zhao et al. [64] reported
on the use of ex vivo expanded autologous BMMCs in the
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treatment of collapse or end stage (ARCOIIC-V) AVNFH.
The cells were implanted in combination with a vascularized
bone graft into the debrided necrotic area of the femoral
head. A titanium rod was also used to augment this con-
struct. They reported a high 5-year survival rate and a signifi-
cant improvement in HHS in the surviving hips (from a
mean of 39.84 to 79.11 points for ARCO stage IIIC hips,
and from a mean of 37.0 to 74.25 points for stage IV hips).
Disease progression occurred in only 15.8% (3 of the 19) of
stage 3C hips and overall 5 of the 31 hips (16.1%) were
converted to THA (2 stage IIIC hips and 3 stage IV hips).
Although they did not have a control group, the results in
this case series is better than that reported historically for
vascularized graft alone [65]. However, the authors acknowl-
edged this high success rate was confounded by the multiple
procedures carried out in addition to the use of BMMCs.
Hence it’s difficult to define the exact therapeutic contribu-
tion of BMMCs to the overall outcome.
In AVNFH, the BMMCs are implanted directly into the
necrotic area of the femoral head. Tracking studies of these
cells in patients showed 56% of installed cells remained in
the implantation site 24 h after implantation [12].
Tracking studies in animals also demonstrated the survival
and multiplications of these cells 12 weeks post implant-
ation [66]. Other surgeons however, have used targeted in-
fusion of peripheral blood stems cells (PBSCs) [15] and
BMMCs [67] through the medial circumflex artery. Cells
have been tracked to the necrotic femoral head following
intravenous infusion in animal models [68], but this has
not been verified in human patients [15, 67], and this
therefore might have an implication on the quantities of
cells reaching and residing in the necrotic area. This is im-
portant because Hernigou et al. [60] reported an associ-
ation between the outcome of AVNFH and the quantity of
cells transplanted into the femoral head and recommended
a specific minimum number of oestrogenic precursor cells
transplantation [14, 69]. No studies have compared dir-
ectly implanted cells into the necrotic area with cells indir-
ectly transplanted via targeted arterial infusion. However
direct comparison between the use of concentrated
BMMCs versus unprocessed bone marrow aspirate has
shown a better clinical outcome with processed (concen-
trated) BMMCs [17], yielding further support for the im-
portance of high BMMCs concentrate transplantation.
This may also highlight the importance of ex vivo cells ex-
pansion (prior transplantation) in patients who have low
BMMCs concentration (such as in cases of steroid and al-
cohol induced AVNFH [70]) in order to overcome the
inconsistencies in the number of cells transplanted [13, 60,
71]. This literature search was unable to identify control
studies comparing the outcome of ex vivo expanded cells
with processed and concentrated BMMCs directly from
bone marrow aspirate.
In the studies reviewed, no serious adverse events in as-
sociation with the use of cell therapy in the treatment of
AVNFH (especially with regards to malignancy) have been
reported. However, it must be stressed that only the short-
and the mid-term results have been published so far.
Autologous chondrocyte implantation
Autologous chondrocyte implantation (ACI) involves ini-
tial debridement and harvest followed by transplantation of
culture expanded chondrocytes into the chondral defect.
Chondrocytes are either sealed with periosteum or are de-
livered bound to a layer of collagen-matrix [22, 41, 42, 56].
The first case report of using ACI for the treatment of a
femoral head articular defect was published by Akimau
et al. [44]. Following anterior dislocation of the hip joint,
the defect was debrided, filled with bone graft and sealed
with a collagen patch. Six million chondrocytes were in-
jected under the patch. The patient’s HSS improved from
52 (pre-operatively) to 76 points, 16 months following the
procedure, and was able to run and walk more than a mile.
Full depth histological biopsy from the ACI treated site 15
months post-surgery demonstrated predominantly fibro-
cartilage of 2-mm thickness, fully integrated with the
underlying bone and contained viable cells.
The largest case series of arthroscopic autologous chon-
drocyte transplantation in the hip joint was reported by
Ko¨rsmeier et al. [42]. Autologous matrix-induced 3D chon-
drocyte transplantation spheroids (ACT 3D) were used to
treat 16 hips with acetabular chondral defects induced by
CAM-type femoroacetabular impingement (FAI). The car-
tilage was harvested from the cam lesion and sent to an off-
site centre for chondrocyte culture into 3D spheroids over
a period of 5–10 weeks (each spheroid contained 200 000
chondrocytes). A second stage arthroscopy was carried out
to debride the defect and deliver the spheroids using a flex-
ible needle. The average size of the chondral defects was
4.52 cm2 (range 3–6 cm2). There was a significant im-
provement in the WOMAC and NAHS 6 and 12 weeks
after grafting (P< 0.001 and< 0.001, respectively). These
scores were maintained after a mean follow-up period of
16.09 months (range 9.5–28.8 months). The outcome of
surgery with regard to pain relief, restoration of mobility
and ability to perform sporting activities was reported by
patients as excellent in eight cases, very good in four, good
in three and fair in one case [42].
There is only one comparison study involving ACI,
published by Fontana et al. [22]. They retrospectively com-
pared the outcome of ACI to simple microfracture in pa-
tients who had third or fourth degree (Outerbridge
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classification) chondral lesions of 2 cm2 or more. An initial
arthroscopy was carried out to grade and debride the lesion
and to obtain a cartilage biopsy from the pulvinar. The
cells were expanded and subsequently implanted using a
3D polymer scaffold during a second arthroscopic proced-
ure. The mean follow-up was 6 years for both groups
(73.8 months in the ACI group and 74.3 months in the de-
bridement group). There was a statistically significant dif-
ference in the mean HHS at the end of the follow-up
between the two groups (P< 0.001) (Table III). No post-
procedure radiological or arthroscopic evaluations for these
patients were carried out.
Mosaicplasty and osteochondral transplantation
Although mosaicplasty and osteochondral transplant (OT)
do not fit the definition of an ‘orthobiologic’ but were
identified in the search strategy and are included here for
completeness and relevance to the emerging field of hip
preservation.
OT in the femoral head and the acetabular dome has
been reported in various case reports and case series [23–
33, 49–51]. Authors recommended OT for small articular
cartilage defects with stable and well perfused sub-chondral
bone surrounded by a stable bed of cartilage [72].
Mosaicplasty involves the use of multiple small osteochon-
dral plugs to treat larger lesions. The articles identify that it
is important to restore the original geometry and curvature
of the femoral head or acetabular surface [27, 72].
Therefore grafts are ideally harvested from a donor source
that resembles the original curvature of the defective articu-
lar surface. Hence, many harvest the autologous graft from
the non weight bearing portion of the femoral head or an
allograft from the same corresponding area on the femoral
head or the acetabular dome. Similarly, mosaicplasty plugs
harvested from the knee joint are arranged in a way to re-
store the natural curvature of the femoral head [27].
Kosashvili et al. [25] published a case series of eight pa-
tients who received OT for chondral lesions in the femoral
head. The procedure involved trochanteric osteotomy and
open dislocation of the hip followed by debridement and
reaming of the osteochondral defect. Matching size fresh-
stored osteochondral allograft was implanted using a press
fit technique. Follow-up ranged from 24 to 54 months
(mean; 41 months). The mean HHS improved from 57.7
(range 50–65) points pre-operatively to 83.9 (range 72–
94) points at the latest follow-up. The procedure failed in
two patients, one of whom needed THA 6 month after the
procedure. The failure in the second patient was attributed
to non-compliance with the rehab protocol resulting in
subsidence of the graft. Hence a revision osteochondral
allograft transfer was performed.
The largest case series with the longest follow-up for
OT has been reported by Mayers et al. [28]. They used
allogeneic osteohondral graft to treat 25 hips, all (except
one) had segmental collapse of the femoral head secondary
to AVNFH. They reported a 32% failure rate over a fol-
low-up period ranging between 9 and 63 months. In total
50% of failures occurred in patients with AVNFH second-
ary to fractured neck of femur or steroids, all occurring
within the first 18 months after treatment.
For femoral head mosaicplasty, the largest case series
was published by Girard et al. [27]. They reported the clin-
ical outcome of treating 10 patients by open anterior dis-
location of the femoral head and mosaicplasty. The size of
the lesions ranged from 3 to 9 cm2 (mean 4.8 cm2).
Osteochondral plugs (8–10mm) were harvested from the
non-weight bearing portion of the femoral head. After a
mean follow-up period of 29.2 (range, 20–33) months
there was an improvement in the Postel Merle d’Aubigne
score and the HSS from 10.5 and 52.8 pre-operatively, to
15.5 and 79.5, respectively. There was also a decrease in
the Oxford Hip Score indicating improvement in function
34.5 (22–48) to 19.2 (14–26) and improvement in pa-
tients activity of daily living. Radiological assessment re-
vealed an excellent incorporation of the graft and smooth
articulating surface with no evidence of collapse.
The treatment of chondral defects in the acetabula dome
using osteochondral allograft has so far been described in
two reports [26, 33]. Krych et al. [26] used fresh stored,
non-irradiated osteochondral allografts that were press fitted
into the defects without supplementary fixation. MRI scans
at 12 and 18 months demonstrated incorporation of the
osteochondral allograft to the host bone with maintenance
of joint congruity. The two patients had HSS of 97 and 100
at the end of 2 and 3 years follow-up, respectively.
A technique for arthroscopic assisted autologous OT
for the femoral head has also been reported [31]. In this
procedure, a tunnel is created from the lateral cortex of the
femur via the femoral neck and into the chondral defect.
Reporting on two patients, the autologous osteochondral
plug was harvested from the knee joint and passed retro-
gradely through the femoral neck tunnel into the chondral
defect in the femoral head. After at least 2-year follow-up,
the HSS improved from 56.6 and 88.6 pre-operatively, to
87.6 and 90, respectively. Neither of the patients had sig-
nificant symptoms at the last follow-up.
Other non-invasive hip preservation procedures
Autologous matrix-induced chondrogenesis
Autologous matrix-induced chondrogenesis (AMIC) is a
procedure that involves microfracture of the sub-chondral
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bone and a type I/III collagen matrix is placed over the de-
fect to provide a ceiling for and to support the haematoma
that arises from microfracture [56]. It also provides a skel-
eton for repair and tissue formation. AMIC is carried out
as a single stage procedure and does not involve implant-
ation of chondrocytes which distinguishes it from ACI and
MACI. The procedure is indicated for grade III or IV
chondral lesions (Outerbridge classification) with sizes be-
tween 2 and 8 cm2. Fontana et al. [56] described arthro-
scopic AMIC for chondral lesions in the hip joint but so
far there have been no published clinical outcome results
of hips treated with this procedure.
Delaminated articular cartilage repair
Stafford et al. [54] reported on the arthroscopic repair of
fully ‘enclosed’ delaminated acetabular cartilage using fibrin
adhesive glue. The process involves microfracture of the sub-
chondral bone behind the delaminated cartilage and subse-
quent injection of the fibrin adhesive into the cartilage
pocket. The delaminated chondral surface is then firmly
pressed against the chondral bone for 2 min. The outcome
of this technique was reported in 43 patients who had an
underpinning CAM lesion causing the delamination of the
cartilage. After a mean follow-up of 28 months, there was a
significant improvement in MHHS from 61.9 points to 79.4
and a significant improvement in MHHS for pain (P< 0.001
P¼ 0.006, respectively). Arthroscopic review of the repair in
three patients (during a late arthroscopic iliopsoas release)
demonstrated good repair of the chondral defects.
Sekiya et al. [55] described a suture repair of 1-cm
delaminated cartilage flap in the anterior-superior acetabu-
lum in a young patient with FAI. They carried out a micro-
fracture of the sub-chondral bone underneath the flap
before suturing it with an absorbable polydiaxanone mono-
filament. The patient reported 95% of normal function
after 2 years of follow-up and good hip function scores
(MHHS of 96, HOSADL of 93 and HOSSSS of 81).
CONCLUSION
Orthobiologics is a difficult term to accurately define. We
have used a systematic search of the literature to identify
potentially relevant topics and then selected those most ap-
plicable to hip preservation surgery. In terms of the topics,
we identified several innovative strategies that span discip-
lines from cell therapy to material approaches. However,
the majority of the literature identified addressed the treat-
ment of AVN of the femoral head which represent only a
small proportion of hip preservation surgery. Furthermore,
it is not clear to the authors that the term orthobiologics
represents a useful term when compared with other similar
and overlapping terms e.g. regenerative medicine, which
has a more precise but also more focused definition.
Although the identified treatments may offer enormous
potential for the future, when it comes to current practice
the situation is not clear. The literature is dominated by
level 3 and 4 evidence mainly in the form of short-term
outcome results. There was a lack of comparative clinical
trial data to inform evidence-based practice. Similar strat-
egies are more clearly understood in the knee and it would
seem appropriate to infer that they would be similarly use-
ful in the hip, with supporting evidence. Hence there is an
urgent need for better well constructed studies to establish
the effectiveness of these orthobiologics and to refine their
application in hip preservation surgery.
Finally, the exciting field of orthobiologics in joint pres-
ervation procedures brings with it regulatory and safety
issues that will need to be successfully addressed. In this re-
view, none of the studies reported any major adverse
events but the quality of the evidence remains inadequate
with long term safety data still required.
In summary orthobiologics, as set out in this account, is
an overarching term for many approaches that offer a new
and exciting direction for orthopaedic surgery in general
and hip preservation specifically. However, the innovation
must be carefully adopted by responsible translation. This
will require robust clinical trial data to support both effect-
iveness and cost-effectiveness and needs to be underpinned
by appropriate regulatory and safety data.
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